Centro Hospitalar E Universitario De Coimbra E.P.E.
- Address
- Praceta Professor Mota Pinto, 3004-561 Coimbra, Portugal
Cardiovascular Diseases
The Centro Hospitalar E Universitario De Coimbra E.P.E. Neurology department is conducting research aimed at preventing and treating cerebrovascular events, with a focus on acute ischemic stroke and high‑risk transient ischemic attack. A key study evaluates the safety and efficacy of milvexian to lower the risk of recurrent stroke.
- Acute Ischemic Stroke
- High‑Risk Transient Ischemic Attack
- Antithrombotic Therapy Development
- Risk Reduction Strategies
Investigators are exploring novel anticoagulant approaches to improve outcomes for patients at high risk of cardiovascular complications.
Nervous System Diseases
In the realm of neurodegenerative and epileptic disorders, the site is testing innovative therapies for Alzheimer's disease and primary generalized tonic‑clonic seizures. One trial measures amyloid reduction with ABBV‑916 in early Alzheimer’s, while another assesses the impact of XEN1101 on seizure frequency.
- Early Alzheimer’s Disease
- Amyloid Targeting Strategies
- Primary Generalized Tonic‑Clonic Seizures
- Seizure Frequency Reduction
The multidisciplinary team aims to bring disease‑modifying treatments to patients with cognitive decline and epilepsy.
Virus Diseases
The hospital participates in an adaptive platform trial addressing COVID‑19, evaluating therapeutic options for both moderate and severe disease. A specific protocol compares baricitinib plus standard of care against placebo in immunocompromised patients with critical illness.
- Moderate COVID‑19
- Severe/Critical COVID‑19
- Adaptive Pandemic Platform
- Immunocompromised Patient Care
These efforts contribute to global knowledge on effective interventions during the pandemic and support vulnerable patient groups.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 20 therapeutic areas and 15 of 320 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 310 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 67 by active trials.
- 1Boehringer Ingelheim Espana S.A.7active
lock +66 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG14trials
lock +33 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar E Universitario De Coimbra E.P.E.
lock Showing 1 of 182 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 320 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 9 | Unknown | 2015-11-06 | 2025-09-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.